CR1 is potentially associated with rate of decline in sporadic Alzheimer's disease

Journal of Clinical Neuroscience

Volumn 21, Issue 10, 2014, Pages 1705-1708

  Schmidt, Christian ^a   Wolff, Martin ^a   Von Ahsen, Nicolas ^a   Lange, Katharina ^a   Friede, Tim ^a   Zerr, Inga ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer; CR1; Polymorphism; Progression; SNP

Indexed keywords

APOLIPOPROTEIN E; CLUSTERIN; COMPLEMENT COMPONENT C3B RECEPTOR; CYSTATIN; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN RECEPTOR; CR1 PROTEIN, HUMAN;

ACE GENE; AGED; ALZHEIMER DISEASE; APOE GENE; ARTICLE; BIN1 GENE; CLINICAL ARTICLE; CLU GENE; CONTROLLED STUDY; CR1 GENE; CST3 GENE; EXOC3L2 GENE; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GWA14Q32.13 GENE; HETEROZYGOTE; HUMAN; IL8 GENE; LDLR GENE; MALE; MINI MENTAL STATE EXAMINATION; PICALM GENE; PROGNOSIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TNK1 GENE; COHORT ANALYSIS; DISEASE COURSE; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; GENOTYPING TECHNIQUE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PSYCHOLOGICAL RATING SCALE; REGRESSION ANALYSIS;

AGED; ALZHEIMER DISEASE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPING TECHNIQUES; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, COMPLEMENT 3B; REGRESSION ANALYSIS;

EID: 84908540404     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2014.03.015     Document Type: Article

References (30)

1. Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013;80:1778-83.
2. Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer's disease. Hum Mol Genet 2009;18:R137-45.
3. Schmidt C, Wolff M, von Ahsen N, et al. Alzheimer's disease: genetic polymorphisms and rate of decline. Dement Geriatr Cogn Disord 2012;33:84-9.
4. Gauthier S, Dubois B, Feldman H, et al. Revised research diagnostic criteria for Alzheimer's disease. Lancet Neurol 2008;7:668-70.
5. Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007;39:17-23.
6. Bertram L, McQueen MB, Mullin K, et al. The AlzGene database. Alzheimer Research Forum; 2010. Available from: http://www.alzgene.org.
7. Schütz E, von Ahsen N. Spreadsheet software for thermodynamic melting point prediction of oligonucleotide hybridization with and without mismatches. Biotechniques 1999;27:1218-22. 1224.
8. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357-67.
9. Bretz F, Hothorn T, Westfall P. Multiple comparisons using R. Boca Raton, FL, USA: Chapman & Hall/CRC Press Inc.; 2010. pp 106-7.
10. Schmidt C, Wolff M, Weitz M, et al. Rapidly progressive Alzheimer disease. Arch Neurol 2011;68:1124-30.
11. Sweet RA, Seltman H, Emanuel JE, et al. Effect of Alzheimer's disease risk genes on trajectories of cognitive function in the Cardiovascular Health Study. Am J Psychiatry 2012;169:954-62.
12. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-44.
13. Krych-Goldberg M, Atkinson JP. Structure-function relationships of complement receptor type 1. Immunol Rev 2001;180:112-22.
14. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-98.
15. Shen Y, Lue L, Yang L, et al. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett 2001;305:165-8.
16. Rogers J, Cooper NR, Webster S, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992;89:10016-20.
17. Keenan BT, Shulman JM, Chibnik LB, et al. A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline. Hum Mol Genet 2012;21:2377-88.
18. Crehan H, Hardy J, Pocock J. Blockage of CR1 prevents activation of rodent microglia. Neurobiol Dis 2013;54:139-49.
19. Karch CM, Jeng AT, Nowotny P, et al. Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS One 2012;7:e50976.
20. Daborg J, Andreasson U, Pekna M, et al. Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. J Neural Transm 2012;119:789-97.
21. Chibnik LB, Shulman JM, Leurgans SE, et al. CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol 2011;69:560-9.
22. Jun G, Naj AC, Beecham GW, et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 2010;67:1473-84.
23. Hu X, Pickering EH, Hall SK, et al. Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment. Transl Psychiatry 2011;1:e54.
24. Wilkosz PA, Seltman HJ, Devlin B, et al. Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr 2010;22:281-90.
25. Cosentino S, Scarmeas N, Helzner E, et al. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 2008;70:1842-9.
26. Stern Y, Brandt J, Albert M, et al. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997;41:615-20.
27. Musicco M, Salamone G, Caltagirone C, et al. Neuropsychological predictors of rapidly progressing patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2010;30:219-28.
28. Bernick C, Cummings J, Raman R, et al. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol 2012;69:901-5.
29. Rosenberg PB, Mielke MM, Han D, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. Int J Geriatr Psychiatry 2012;27:1248-57.
30. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46.